Connect Biopharma Holdings Limited (CNTB) annual income statement — 7-year revenue, gross profit & net income history
Connect Biopharma Holdings Limited (CNTB) annual income statement — 7-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 |
|---|
| Sales/Revenue | 3.68M | 64K | 26.03M | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | -99.75% | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | 3.68M | 64K | 26.03M | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | 100% | 100% | - | - | - | - | - |
| Gross Profit Growth % | - | -99.75% | - | - | - | - | - | - |
| Operating Expenses | 79.46M | 58.14M | 48.48M | 69.06M | 119.32M | 98.11M | 29.36M | 16.44M |
| OpEx % of Revenue | - | 90840.63% | 186.24% | - | - | - | - | - |
| Selling, General & Admin | 17.12M | 20.34M | 19.23M | 16.05M | 20.81M | 19.01M | 7.31M | 1.41M |
| SG&A % of Revenue | - | 31781.25% | 73.86% | - | - | - | - | - |
| Research & Development | 42.56M | 37.8M | 29.26M | 53M | 96.63M | 80.5M | 23.12M | 15.44M |
| R&D % of Revenue | - | 59059.38% | 112.38% | - | - | - | - | - |
| Other Operating Expenses | 1000K | 0 | 0 | 0 | 1.88M | -1.4M | -88.74M | -8.62M |
| Operating Income | -75.78M | -58.07M | -22.45M | -69.06M | -119.32M | -98.11M | -30.3M | -15.99M |
| Operating Margin % | - | -90740.63% | -86.24% | - | - | - | - | - |
| Operating Income Growth % | - | -158.66% | 67.49% | 42.12% | -21.62% | -223.84% | -89.42% | - |
| EBITDA | -74.92M | -57.37M | -21.79M | -68.34M | -118.28M | -97.47M | -30.07M | -15.88M |
| EBITDA Margin % | - | -89640.63% | -83.71% | - | - | - | - | - |
| EBITDA Growth % | - | -163.26% | 68.11% | 42.23% | -21.35% | -224.11% | -89.4% | - |
| D&A (Non-Cash Add-back) | 861K | 704K | 660K | 720K | 1.03M | 634K | 221.05K | 114.61K |
| EBIT | -73.94M | -55.28M | -15.4M | -61.99M | -117.77M | -201.99M | 0 | 0 |
| Net Interest Income | 6.61M | 2.27M | 4.45M | 5.2K | 1.54M | 90.76K | 103.4K | 146.96K |
| Interest Income | 6.61M | 2.27M | 4.45M | 5.2K | 1.56M | 97.67K | 109.84K | 154.65K |
| Interest Expense | 0 | 0 | 0 | 0 | 21.03K | 6.91K | 6.43K | 7.69K |
| Other Income/Expense | 2.48M | 2.79M | 7.05M | 7.07M | 1.52M | -103.89M | -89.68M | -8.17M |
| Pretax Income | -73.3M | -55.28M | -15.4M | -61.99M | -117.79M | -202M | -119.37M | -24.46M |
| Pretax Margin % | - | -86379.69% | -59.17% | - | - | - | - | - |
| Income Tax | 296K | 197K | 223K | 120K | 298K | 266K | 0 | 0 |
| Effective Tax Rate % | -0.4% | -0.36% | -1.45% | -0.19% | -0.25% | -0.13% | 0% | 0% |
| Net Income | -73.6M | -55.48M | -15.63M | -62.11M | -118.09M | -202.27M | -119.37M | -24.46M |
| Net Margin % | - | -86687.5% | -60.03% | - | - | - | - | - |
| Net Income Growth % | - | -255% | 74.84% | 47.41% | 41.62% | -69.45% | -387.95% | - |
| Net Income (Continuing) | -73.6M | -55.48M | -15.63M | -62.11M | -118.09M | -202.27M | 0 | 0 |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | - | -1.00 | -0.28 | -1.08 | -14.50 | -25.00 | -14.45 | -3.02 |
| EPS Growth % | - | -257.14% | 74.07% | 92.55% | 42% | -73.01% | -378.48% | - |
| EPS (Basic) | - | -1.00 | -0.28 | -1.08 | -14.50 | -25.00 | -14.45 | -3.02 |
| Diluted Shares Outstanding | 62.88M | 55.66M | 55.21M | 55.07M | 55.04M | 52.27M | 53.94M | 55.82M |
| Basic Shares Outstanding | 62.88M | 55.66M | 55.21M | 55.07M | 55.04M | 52.27M | 53.94M | 55.82M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying CNTB stock.
For fiscal year 2025, Connect Biopharma Holdings Limited (CNTB) reported total revenue of $0.1M.
Connect Biopharma Holdings Limited (CNTB) reported a net loss of $55.5M for the fiscal year ending 2025.
Connect Biopharma Holdings Limited (CNTB) reported an operating income of $-58.1M, resulting in an operating profit margin of -90740.6%. This margin reflects the operational efficiency of the business before interest and taxes.
Connect Biopharma Holdings Limited (CNTB) generated $0.1M in gross profit for the year, representing a gross profit margin of 100.0%. This demonstrates the company's core pricing power and production efficiency.